

Synthesis, Pharmacological Evaluation, and Computational Studies of Cyclic Opioid Peptidomimetics Containing β^3 -Lysine

Karol Wtorek ¹, Piotr F. J. Lipiński ², Anna Adamska-Bartłomiejczyk ¹, Justyna Piekielna-Ciesielska ¹, Jarosław Sukiennik ³, Alicja Kluczyk ⁴ and Anna Janecka ^{1,*}

¹ Department of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland; karol.wtorek@umed.lodz.pl (K.W.); anna.adamska@umed.lodz.pl (A.A.-B.); justyna.piekielna@umed.lodz.pl (J.P.-C.)

² Department of Neuropeptides, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland; plipinski@imdik.pan.pl

³ TriMen Chemicals Ltd., 92-318 Lodz, Poland; sukiennik@trimen.pl

⁴ Faculty of Chemistry, University of Wroclaw, 50-383 Wroclaw, Poland; alicja.kluczyk@chem.uni.wroc.pl

* Correspondence: anna.janecka@umed.lodz.pl

Contents

- ¹H NMR spectrum of Fmoc-(R)- β^3 -Lys(Mtt) (Figure S1)..... p. S2
- Physicochemical characterization of analogs **2-9** (Table S1)..... p. S3
- High resolution mass spectra of analogs **RP-171** and **RP-172** (Figure S2 and S3)..... p. S4
- LC-MS and MSⁿ analysis of analogs **RP-171** and **RP-172** (Figure S4-S6).....p. S6
- Total energies of top 15 conformers for **RP-171** and **RP-172**, obtained at the B3LYP/6-31G(d,p) level (Table S2)..... p. S9
- Concentration-response curves of analogs in the functional assay (Figure S7)p. S10
- Root mean square deviations (RMSD) of protein (top) and ligand (bottom) positions for MD simulations of **RP-171** and **RP-172** with MOR (Figure S8).....p. S11
- References.....p. S12




Figure S1. ^1H NMR spectrum of Fmoc-(*R*)- β^3 -Lys(Mtt).




Figure S2. Analysis of peptide Tyr-c[(*R*)- β^3 Lys-Phe-Phe-Asp]NH₂ (RP-171) by mass spectrometry. High resolution MS spectrum. In inset, fragment of the experimental spectrum is compared with the simulated isotopic profile calculated for the expected molecular formula of protonated species [M+H]⁺.




Figure S3. Analysis of peptide of peptide Tyr-c[(S)-β³Lys-Phe-Phe-Asp]NH₂ (RP-172).

High resolution MS analysis. In inset, fragment of the experimental spectrum is compared with the simulated isotopic profile calculated for the expected molecular formula of protonated species [M+H]⁺.




Figure S4. LC-MS analysis of peptide Tyr-c[(R)-β³Lys-Phe-Phe-Asp]NH₂ (RP-171). Top panel: total ion chromatogram (TIC, blue line) and extracted ion chromatogram for *m/z* 700.345 (XIC, green line). MSⁿ spectra recorded for the retention time in XIC. Kinetex Biphenyl column was used for chromatographic separation.




Figure S5. LC-MS analysis of peptide Tyr-c(S)- β^3 Lys-Phe-Phe-Asp]NH₂ (RP-172). Top panel: total ion chromatogram (TIC, blue line) and extracted ion chromatogram for m/z 700.345 (XIC, green line). MSⁿ spectra recorded for the retention time in XIC. Kinetex Biphenyl column was used for chromatographic separation.




Figure S6. LC-MS analysis of peptide mixture, containing Tyr-c(*R*)- β^3 -Lys-Phe-Phe-Asp]NH₂ (**RP-171**) and Tyr-c(*S*)- β^3 -Lys-Phe-Phe-Asp]NH₂ (**RP-172**). Top panel: total ion chromatogram (TIC, blue line) and extracted ion chromatogram for *m/z* 700.345 (XIC, green line). MSⁿ spectra recorded for the retention times in XIC. Kinetex Biphenyl column was used for chromatographic separation.




Figure S7. Concentration-response curves to reference agonists and tested peptides in calcium mobilization experiments performed in CHO cells stably co-expressing the human MOR (Panel A) or KOR (Panel B) and the C-terminally modified $G\alpha_{q15}$ and CHO cells co-expressing DOR (Panel C) and the $G\alpha_{qG66D15}$ protein. Data are the mean \pm SEM of at least 4 separate experiments performed in duplicate.




Figure S8. Root mean square deviations (RMSD) of protein (top) and ligand (bottom) positions for MD simulations of **RP-171** and **RP-172** with MOR.

Table S1. Physicochemical characterization of analogs.

No.	Sequence	Formula	$m/z [M + H]^{+a}$		HPLC t_R^b [min]
			Calcd	Obsd	
RP-171	Tyr-c[(<i>R</i>)- β^3 Lys-Phe-Phe-Asp]NH ₂	C ₃₇ H ₄₄ N ₇ O ₆	700.3453	700.3454	14.05
RP-172	Tyr-c[(<i>S</i>)- β^3 Lys-Phe-Phe-Asp]NH ₂	C ₃₇ H ₄₄ N ₇ O ₆	700.3453	700.3465	14.36

^a Observed by ESI MS⁺ ionization. Mass spectra of peptides were recorded using Shimadzu IT-TOF mass spectrometer equipped with ESI ion source and operated in positive ion mode.

^b RP-HPLC was performed on a Vydac C₁₈ column (5 μ m, 4.6 x 250 mm) using the solvent system of 0.1% TFA in water (A) and 80% acetonitrile in water containing 0.1% TFA (B) and a linear gradient of 0–100% solvent B over 50 min, with a flow rate of 1 mL/min.

In the MS³ experiment, the 292 m/z ion corresponds to Tyr- β^3 -Lys fragment, 451 m/z and 337 m/z ion are probably formed by removal of Tyr from the 586 m/z ion and internal cyclization, whereas 311 m/z ion represents fragment containing Phe and Tyr residues, formed during internal rearrangement, a frequent occurrence in MS analysis of cyclic peptides [1,2,3,4]. There are at least two pathways in 586 m/z ion fragmentation, with the internal cyclization as well as rearrangement leading to Tyr-Phe fragment formation predominant in **RP-172**, probably resulting from a more stable structure due to orientation of Tyr residue, although a final assignment requires additional MSⁿ studies.

Table S2. Total energies of top 15 conformers for **RP-171** and **RP-172**, obtained at the B3LYP/6-31G(d,p) level.

	Conformer code	Total energy (Hartrees)
RP-171		
1	RP-171 31	-2347.500135
2	RP-171 43	-2347.500042
3	RP-171 25	-2347.494393
4	RP-171 39	-2347.493544
5	RP-171 12	-2347.489088
6	RP-171 92	-2347.487881
7	RP-171 56	-2347.485198
8	RP-171 60	-2347.484992
9	RP-171 96	-2347.483326
10	RP-171 30	-2347.479364
11	RP-171 27	-2347.474592
12	RP-171 3	-2347.474055
13	RP-171 35	-2347.473866
14	RP-171 0	-2347.473614
15	RP-171 72	-2347.472941
RP-172		
1	RP-172 20	-2347.502704
2	RP-172 41	-2347.498904
3	RP-172 84	-2347.498412
4	RP-172 62	-2347.498134
5	RP-172 11	-2347.496409
6	RP-172 8	-2347.495252
7	RP-172 31	-2347.493671
8	RP-172 37	-2347.493462
9	RP-172 56	-2347.493301
10	RP-172 49	-2347.493077
11	RP-172 6	-2347.492747
12	RP-172 51	-2347.492158
13	RP-172 71	-2347.491597
14	RP-172 70	-2347.49103
15	RP-172 64	-2347.490503

References

1. Ngoka, L. C. M.; Gross, M. L. Multistep Tandem Mass Spectrometry for Sequencing Cyclic Peptides in an Ion-Trap Mass Spectrometer. *J. Am. Soc. Mass. Spectrom.* **1999**, *10*, 732-746.
2. Jia, C.; Qi, W.; He, Z.; Qiao, B. Sequencing peptides by electrospray ion-trap mass spectrometry: A useful tool in synthesis of Axinastatin 3. *Cent. Eur. J. Chem.* **2006**, *4*, 620-631.
3. Stefanowicz, P. Electrospray mass spectrometry and tandem mass spectrometry of the natural mixture of cyclic peptides from linseed, *Eur. J. Mass. Spectrom.* **2004**, *10*, 665-671.
4. Eckart, K. Mass spectrometry of cyclic peptides. *Mass Spectrom. Rev.* **1994**, *13*, 23-55.